Oxaliplatin is a third-generation platinum compound with proven antitumor activity in the treatment of colorectal cancer. The occurrence of life-threating hemolitic uremic syndrome has been observed after oxaliplatin therapy. The kind of tumor and treatment modalities seem to influence the onset of hemolitic uremic syndrome.
Methods
The clinical course of the case is reviewed and compared with reports of other similar cases in the literature.
Results
We describe the development of hemolitic uremic syndrome as a result of prolonged oxaliplatin treatment of a colon cancer patient.
Conclusions
Although this rare event requires the concurrence of other unknown factors, it should be considered in a decision-making setting.
CassidyJ., MissetJ.L.: Oxaliplatin-related side effects: characteristics and management.Semin Oncol, 29(5 Suppl 15) 11–20, Oct 2002.
3.
HollenbeckM., KutkuhnB.: Haemolytic-uraemic syndrome and thrombotic-thrombocytopenic purpura in adults: clinical findings and prognostic factors for death and end-stage renal disease.Nephrol Dial Transplant, 13: 76–81, 1998.
4.
SensY.A., MiorinL.A., SilvaH.G., MalheirosD.M., FilhoD.M., JaburP.: Acute renal failure due to hemolytic uremic syndrome in adult patients.Renal Fail, 19: 279–282, 1997.
5.
Bancroft LesesneJ., RothschildN.: Cancer-associated hemolytic-uremic syndrome: analysis of 85 cases from a national registry.JCO, 7: 781–789, 1989.
SaifM.W., McGeeP.J.: Hemolytic-uremic syndrome associated with gemcitabine: A case report and review of literature.JOP, 6: 369–374, 2005.
8.
CoboF., De CelisG.: Emolytic anemia: a oxaliplatin-induced immune anemia a case report and review of the literature.Anticancer Drugs, 18: 973–976, 2007.
9.
DahabrehI., TsoutsosG., TseligasD., JaninisD.: Haemolytic uremic syndrome following the infusion of oxaliplatin: case report.BMC Clin Pharmacol, 6: 5, 2006.
SorbyeH., BruserudO., DahlO.: Oxaliplatin-induced haematological emergency with an immediate severe thrombocytopenia and haemolysis.Acta Oncol, 49: 882–883, 2001.
ChenV.M., ThriftK.M., Morel-KoppM.C., JacksonD., WardC.M., FlowerR.L.: An immediate hemolytic reaction induced by repeated administration of oxaliplatin.Transfusion, 44: 838–843, 2004.
16.
HofheinzR.D., NguyenX.D., BuchheidtD., KerowganM., HehlmannR., Hochhaus: Two potential mechanisms of oxaliplatin-induced haemolytic anaemia in a single patient.Cancer Chemother Pharmacol, 53: 276–277, 2004.
NoronhaV., BurtnessB., MurrenJ., DuffyT.P.: Oxaliplatin induces a delayed immune-mediated hemolytic anemia: a case report and review of the literature.Clin Colorectal Cancer, 5: 283–286, 2005.
20.
CurtisB.R., KaliszewskJ., MarquesM.B., SaifM.W., NabelleL., BlankJ.: Immune-mediated thrombocytopenia resulting from sensitivity to oxaliplatin.Am J Hematol, 81: 193–198, 2006.
21.
TsaiH.M.: Advances in the pathogenesis, diagnosis and treatment of thrombotic thrombocitopenic purpura.J Am Soc Nephol, 14: 1072–1081, 2003.
22.
GeorgeJ.: How I treat patients with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome.Blood, 96: 1223–1229, 2000.
23.
TostivitI., MougenotB.: Adult haemolytic uraemic syndrome: causes and prognostic factors in the last decade.Nephrol Dial Transplant, 17: 1288–1234, 2002.
24.
MichaelM., ElliotE.J., RidleyG.F., HodsonEM, CraigJ.C.: Interventions for haemolytic uraemic syndrome and thrombotic thrombocytopenic purpura. A systematic review. The Cochrane Collaboration, 2009.
